Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA.
Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA.
Cell Rep. 2019 Apr 9;27(2):631-647.e5. doi: 10.1016/j.celrep.2019.03.045.
Deregulated signal transduction is a cancer hallmark, and its complexity and interconnectivity imply that combination therapy should be considered, but large data volumes that cover the complexity are required in user-friendly ways. Here, we present a searchable database resource of synthetic lethality with a PI3 kinase signal transduction inhibitor by performing a saturation screen with an ultra-complex shRNA library containing 30 independent shRNAs per gene target. We focus on Ras-PI3 kinase signaling with T cell leukemia as a screening platform for multiple clinical and experimental reasons. Our resource predicts multiple combination-based therapies with high fidelity, ten of which we confirmed with small molecule inhibitors. Included are biochemical assays, as well as the IPI145 (duvelisib) inhibitor. We uncover the mechanism of synergy between the PI3 kinase inhibitor GDC0941 (pictilisib) and the tubulin inhibitor vincristine and demonstrate broad synergy in 28 cell lines of 5 cancer types and efficacy in preclinical leukemia mouse trials.
信号转导失调是癌症的一个标志,其复杂性和相互关联性意味着应该考虑联合治疗,但需要以用户友好的方式处理涵盖复杂性的大量数据。在这里,我们通过使用包含每个基因靶点 30 个独立 shRNA 的超复杂 shRNA 文库进行饱和筛选,提供了一个具有 PI3 激酶信号转导抑制剂的合成致死性的可搜索数据库资源。我们专注于 Ras-PI3 激酶信号转导,选择 T 细胞白血病作为筛选平台有多个临床和实验方面的原因。我们的资源以高精度预测了多种基于组合的疗法,其中十种我们已经用小分子抑制剂进行了验证。这包括生化测定,以及 IPI145(duvelisib)抑制剂。我们揭示了 PI3 激酶抑制剂 GDC0941(pictilisib)与微管抑制剂长春新碱之间协同作用的机制,并在 5 种癌症类型的 28 种细胞系中证明了广泛的协同作用,并在临床前白血病小鼠试验中证明了疗效。